Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03196115
Other study ID # BHFS 06-2018
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date August 20, 2018
Est. completion date February 28, 2021

Study information

Verified date February 2023
Source CENTOGENE GmbH Rostock
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hyaline fibromatosis syndrome from the blood


Description:

Hyaline fibromatosis syndrome (HFS) is rare autosomal recessive disease characterized by the deposition of amorphous hyaline material in skin and visceral organs. It represents a disease spectrum with infantile systemic hyalinosis (ISH) being the severe form and juvenile hyaline fibromatosis (JHF) being the mild form. Dermatologic manifestations include thickened skin, perianal nodules, and facial papules, gingival hyperplasia, large subcutaneous tumors on the scalp, hyperpigmented plaques over the metacarpophalangeal joints and malleoli, and joint contractures. ISH shows a severe visceral involvement, recurrent infections, and early death. The lesions appear as pearly papules or fleshy nodules. The severity is variable. Some individuals present in infancy and have additional visceral or systemic involvement, which can lead to early death. These patients may show intractable diarrhea and increased susceptibility to infection. Other patients have later onset of a milder disorder affecting only the face and digits. Additional features include gingival hypertrophy, progressive joint contractures resulting in severe limitation of mobility, osteopenia, and osteoporosis. Histologic analysis of skin lesions shows proliferation of spindle-shaped cells forming strands in a homogeneous and hyaline eosinophilic extracellular material in the dermis. New methods, like mass-spectrometry give a good chance to characterize specific metabolic alterations in the blood of affected patients that allow diagnosing in the future the disease earlier, with a higher sensitivity and specificity. Therefore it is the goal of the study to identify and validate a new biochemical marker from the blood of the affected patients helping to benefit other patients by an early diagnose and thereby with an earlier treatment.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 28, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender All
Age group 2 Months and older
Eligibility Inclusion Criteria: - Informed consent will be obtained from the parents before any study related procedures. - Patients of both gender older than 2 months - The patient has a diagnosis of Hyaline fibromatosis syndrome or a high-grade suspicion for Hyaline fibromatosis syndrome High-grade suspicion present, if one or more inclusion criteria are valid: - Positive family anamnesis for Hyaline fibromatosis syndrome - Coarse facies - Subcutaneous nodule - Gingival fibromatosis - Skeletal muscle atrophy - Progressive flexion contractures Exclusion Criteria: - No Informed consent from the parents before any study related procedures. - Patients of both gender younger than 2 months - No diagnosis of Hyaline fibromatosis syndrome or no valid criteria for profound suspicion of Hyaline fibromatosis syndrome

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Germany Centogene AG Rostock
India NIRMAN Navi Mumbai Institute of Research In Mental And Neurological Handicap/Pediatric Geneticist Mumbai
Sri Lanka Lady Ridgeway Hospital for Children Colombo 8

Sponsors (1)

Lead Sponsor Collaborator
CENTOGENE GmbH Rostock

Countries where clinical trial is conducted

Germany,  India,  Sri Lanka, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sequencing of the Hyaline Fibromatosis Syndrome related gene Next-Generation Sequencing (NGS) of the ANTXR2 gene will be performed. The mutation will be confirmed by Sanger sequencing. 4 weeks
Secondary The Hyaline Fibromatosis Syndrome specific biomarker candidates finding The quantitative determination of small molecules (molecular weight 150-700 kD, given as ng/µl) within a dried blood spot sample will be validated via liquid chromatography multiple reaction-monitoring mass spectrometry (LC/MRM-MS) and compared with a merged control cohort. The statistically best validated molecule will be considered as a disease specific biomarker. 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04971200 - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo Early Phase 1
Active, not recruiting NCT05525741 - Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients N/A
Completed NCT02379793 - Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects Phase 1
Completed NCT01093911 - Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) Phase 1
Completed NCT00147511 - Time To Efficacy and Onset Of Action Of Linezolid Phase 4
Completed NCT02355639 - A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin Phase 1
Completed NCT01764594 - Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus Phase 1
Active, not recruiting NCT05185258 - Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study Phase 4
Completed NCT02985437 - Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin Phase 1
Not yet recruiting NCT06427889 - Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons With Diabetes Phase 4
Completed NCT02518048 - A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris Phase 2
Completed NCT02416258 - A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123) Phase 2